Drug repurposing: An approach to tackle drug resistance inS. typhimurium

Abstract

AbstractDrug resistantS. typhimuriumpose important public health problem. The development of effective drugs with novel mechanism(s) of action is needed to overcome issues pertaining to drug resistance. Drug repurposing based on computational analyses is considered a viable alternative strategy to circumvent this issue. In this context, 1309 FDA‐approved drugs molecules from Mantra 2.0 database were analyzed for this study, againstS. typhimurium. Sixteen compounds having similar profiles of gene expression as quinolones were identified from the database, Mantra 2.0. Further, the pharmacophore characteristics of each resultant molecule were identified and compared with the features of nalidixic acid, using the PharamGist program. Subsequently, the activities of these compounds againstS. typhimuriumDNA gyrase were identified, using molecular docking study. Side effects analysis was also performed for the identified compounds. Molecular dynamics simulation was carried out for the compound to validate its binding efficiency. Further, characterization of screened compound revealed IC50 values in micromolar concentration range, of which flufenamic acid showed comparable in vitro activity alongside ciprofloxacin and nalidixic acid. Thus represent interesting starting points for further optimization againstS. typhimuriuminfections. It may be noted that the results we have obtained are the first experimental evidence of flufenamic acid activity againstS. typhimurium.